10.63
-0.01(-0.09%)
Currency In USD
| Previous Close | 10.64 |
| Open | 10.59 |
| Day High | 10.73 |
| Day Low | 10.08 |
| 52-Week High | 29.56 |
| 52-Week Low | 8.18 |
| Volume | 922,966 |
| Average Volume | 977,828 |
| Market Cap | 810.38M |
| PE | -3.81 |
| EPS | -2.79 |
| Moving Average 50 Days | 10.63 |
| Moving Average 200 Days | 18.58 |
| Change | -0.01 |
If you invested $1000 in Nurix Therapeutics, Inc. (NRIX) since IPO date, it would be worth $559.18 as of June 01, 2025 at a share price of $10.63. Whereas If you bought $1000 worth of Nurix Therapeutics, Inc. (NRIX) shares 3 years ago, it would be worth $1,114.26 as of June 01, 2025 at a share price of $10.63.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Nurix Therapeutics to Participate in the Jefferies Global Healthcare Conference
GlobeNewswire Inc.
May 28, 2025 11:00 AM GMT
SAN FRANCISCO, May 28, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announc
Nurix Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference
GlobeNewswire Inc.
May 15, 2025 11:00 AM GMT
SAN FRANCISCO, May 15, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announc
Nurix Therapeutics Announces Presentations of Clinical Data at the 30th European Hematology Association Congress and the 18th International Conference on Malignant Lymphoma
GlobeNewswire Inc.
May 14, 2025 1:30 PM GMT
SAN FRANCISCO, May 14, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announc